天美传媒

Dr. Wen graduated from the Medical College of St. Bartholomew's Hospital, University of London, in 1981. He completed his internal medicine training at the University of London postgraduate hospitals and his neurology residency in the Harvard-Longwood Neurology Training Program. His research is focused on novel treatments of brain tumors, especially targeted molecular agents. His other clinical interests include neurologic complications of cancer.




 

Dr. Zhang joined UT Southwestern as an assistant professor in September, 2007. He currently serves as the director of BERD (Biostatistics, Epidemiology, and Research Design) for the UTSW CTSA program. He also serves on the NCI Central Institutional Review Board (Adult CIRB – Early Phase Emphasis). 
Dr. Zhang’s research interest in statistical methodology lies in two main areas: Bayesian hierarchical modeling and clinical trial design. He has published multiple papers on the application of Bayesian hierarchical models to disease mapping, joint modeling of longitudinal and survival outcomes, item-response theory for grant review, functional enrichment analysis to detect important pathways, and multi-level modeling to detect factors that impact cancer screening, etc. Another area of his research interest is design methodology for clinical trials to account for various pragmatic issues such as correlated outcomes (clustered and longitudinal), missing data, small sample sizes, historical control, random variability in cluster size, and cost constraints, etc. He has published multiple high quality papers in this area and in 2015 he co-authored a book titled “Sample Size Calculations on Clustered and Longitudinal Outcomes in Clinical Research” (Chapman & Hall, New York). Dr. Zhang has been successful in securing extramural grants as the PI to support his independent research program, examples include an NIH R03 grant to conduct secondary data analysis on VA HIV registry; an NSF grant to build risk prediction model based on electronic health record data; and a PCORI methodology development grant to address pragmatic design issues in stepped-wedge cluster randomized trials.

Dr. Keith Eaton is an oncologist who specializes in treating patients with lung, thyroid, and head and neck cancers. He leads clinical trials that investigate immunotherapies like checkpoint inhibitors, which can take the brakes off a patient’s immune system, and targeted therapies that disrupt the ability of cancer cells to grow and spread from the primary tumor to other parts of the body.